171 related articles for article (PubMed ID: 32666201)
1. Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma.
Tanaka H; Okamoto K; Sato Y; Tanaka T; Tomonari T; Nakamura F; Fujino Y; Mitsui Y; Miyamoto H; Muguruma N; Morita A; Ikushima H; Takayama T
J Gastroenterol; 2020 Nov; 55(11):1072-1086. PubMed ID: 32666201
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
Ikeda M; Kudo M; Aikata H; Nagamatsu H; Ishii H; Yokosuka O; Torimura T; Morimoto M; Ikeda K; Kumada H; Sato T; Kawai I; Yamashita T; Horio H; Okusaka T;
J Gastroenterol; 2018 Feb; 53(2):281-290. PubMed ID: 28766016
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
Tawada A; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Ogasawara S; Suzuki E; Kanai F; Yoshikawa M; Yokosuka O
Anticancer Res; 2015 Jan; 35(1):549-54. PubMed ID: 25550601
[TBL] [Abstract][Full Text] [Related]
4. Initial safety and outcomes of miriplatin plus low-dose epirubicin for transarterial chemoembolisation of hepatocellular carcinoma.
Iwazawa J; Hashimoto N; Ohue S; Mitani T
Anticancer Res; 2012 Nov; 32(11):5039-44. PubMed ID: 23155276
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
Matsumoto T; Ichikawa H; Imai J; Hayashi T; Tomita K; Mine T; Kojima S; Watanabe N; Hasebe T
Anticancer Res; 2017 Jun; 37(6):3183-3187. PubMed ID: 28551662
[TBL] [Abstract][Full Text] [Related]
6. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Imai Y; Chikayama T; Nakazawa M; Watanabe K; Ando S; Mizuno Y; Yoshino K; Sugawara K; Hamaoka K; Fujimori K; Inao M; Nakayama N; Oka M; Nagoshi S; Mochida S
J Gastroenterol; 2012 Feb; 47(2):179-86. PubMed ID: 21976133
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to miriplatin in rat hepatoma AH109A/MP10 is associated with increased Bcl-2 expression, leading to defects in inducing apoptosis.
Hanada M; Takasu H; Kitaura M
Oncol Rep; 2010 Oct; 24(4):1011-8. PubMed ID: 20811683
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
Shirono T; Iwamoto H; Niizeki T; Shimose S; Nakano M; Satani M; Okamura S; Noda Y; Kamachi N; Kuromatsu R; Sakai M; Nomiyama M; Kuwano T; Tanaka M; Koga H; Torimura T
Oncology; 2019; 96(2):79-86. PubMed ID: 30293080
[TBL] [Abstract][Full Text] [Related]
10. Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.
Oguro S; Hashimoto S; Tanaka T; Inoue M; Nakatsuka S; Kuribayashi S; Asakura K; Kawachi S; Tanabe M; Kitagawa Y; Ebinuma H; Saito H; Hibi T
Jpn J Radiol; 2012 Nov; 30(9):735-42. PubMed ID: 22923183
[TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 and oxaliplatin via p53-independent pathway in vitro and in vivo.
Liu X; Xu J; Wang S; Yu X; Kou B; Chai M; Zang Y; Chen D
Int J Oncol; 2017 Oct; 51(4):1291-1299. PubMed ID: 28902369
[TBL] [Abstract][Full Text] [Related]
12. LncRNA H19 modulated by miR-146b-3p/miR-1539-mediated allelic regulation in transarterial chemoembolization of hepatocellular carcinoma.
Song Y; Xing H; Zhou L; Zhang N; Yang M
Arch Toxicol; 2021 Sep; 95(9):3063-3070. PubMed ID: 34251499
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma.
Kamimura K; Suda T; Tamura Y; Takamura M; Yokoo T; Igarashi M; Kawai H; Yamagiwa S; Nomoto M; Aoyagi Y
BMC Gastroenterol; 2012 Sep; 12():127. PubMed ID: 22994941
[TBL] [Abstract][Full Text] [Related]
14. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.
Zhao JD; Liu J; Ren ZG; Gu K; Zhou ZH; Li WT; Chen Z; Xu ZY; Liu LM; Jiang GL
Radiat Oncol; 2010 Feb; 5():12. PubMed ID: 20149262
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
[TBL] [Abstract][Full Text] [Related]
17. Database analysis of patients with hepatocellular carcinoma and treatment flow in early and advanced stages.
Akada K; Koyama N; Taniguchi S; Miura Y; Aoshima K
Pharmacol Res Perspect; 2019 Aug; 7(4):e00486. PubMed ID: 31249691
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.
Fernando J; Sancho P; Fernández-Rodriguez CM; Lledó JL; Caja L; Campbell JS; Fausto N; Fabregat I
J Cell Physiol; 2012 Apr; 227(4):1319-25. PubMed ID: 21604268
[TBL] [Abstract][Full Text] [Related]
19. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
Imai N; Ikeda K; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Jpn J Clin Oncol; 2012 Mar; 42(3):175-82. PubMed ID: 22210921
[TBL] [Abstract][Full Text] [Related]
20. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
